Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070717 | 0.90 | PDE3A (0.47) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL1880455 | 0.89 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27999217 | 0.87 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL18740735 | 0.85 | PDE3A (0.45) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL28780917 | 0.84 | PDE3A (0.45) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL13454615 | 0.83 | PDE3A (0.43) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL13454621 | 0.83 | PDE3A (0.43) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL13454641 | 0.83 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL4248207 | 0.81 | PDE3A (0.40) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL18740733 | 0.81 | PDE3A (0.40) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141676-A1 | THERAPEUTIC mRNA | THE UNIVERSITY OF MELBOURNE (AU) | 2023-08-03 | — | — | WO | claimed |
| EP-0948256-A4 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | UNIV WASHINGTON (US) | 2007-10-24 | — | — | EP | claimed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| WO-2001085220-A1 | LABELED NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | RNA-TEC N.V. (BE) | 2001-11-15 | — | — | WO | claimed |
| JP-2001513568-A | — | — | 2001-09-04 | — | — | JP | claimed |
| EP-1011688-A1 | USE OF URIDINE 5'-DIPHOSPHATE AND ANALOGS THEREOF FOR THE TREATMENT OF LUNG DISEASES | The University of North Carolina at Chapel Hill (US) | 2000-06-28 | — | — | EP | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1999009998-A1 | USE OF URIDINE 5'-DIPHOSPHATE AND ANALOGS THEREOF FOR THE TREATMENT OF LUNG DISEASES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4396349-A1 | COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION | Molecular Axiom, LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999009998-A1 | USE OF URIDINE 5'-DIPHOSPHATE AND ANALOGS THEREOF FOR THE TREATMENT OF LUNG DISEASES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | PDE3A 3818/4885PDE4D 1220/4885SLC29A1 304/4885 |
| US-12595226-B2 | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PCTP, PLTP | PDE3A 3615/4885PDE4D 3735/4885SLC29A1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.